arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

C4 Therapeutics, Inc.

CCCC
$2.96 ▼ -0.16 (-5.13%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
30 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

C4 Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $386.9M
Dividend Yield —
Revenue Growth 2.8% ↗
Op. Margin -397.9% ↗
ROIC -8.4% ↗
FCF / Share $-0.01 ↗
Trailing P/E —
Price / Book 1.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

30-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$6.64M
↑ +2.8% —
Net Income Profit after all expenses
$-25.13M
↑ +4.5% —
Operating Margin Operating profit as % of sales
-397.9%
↑ +11.9% 0th
FCF / Share Free cash flow per share
$-0.01
↑ +92.9% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
0
Returns ↓
19
Cash Quality ↓
63

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 30 quarters